Skip to content
AnalystLens

Merck Annual Report, Year Ended Dec 31, 2002

Filing Date
Filed March 10, 2003
Period End
December 31, 2002
Security
MRK
In the record · 2016–202610-K1210-Q338-K87

MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 87 current reports (8-K) between 2016 and 2026.

  1. Impairment8-K · Feb ’17Feb ’17
  2. Restructuring8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Aug ’21Aug ’21
  4. Restructuring8-K · Jul ’25Jul ’25

Summary

Summary of the 10-K filed March 10, 2003. Cited figures are marked; the original filing is the authoritative source.

Schering-Plough Corporation's 2002 annual report shows consolidated net sales of $10.18 billiona, up 4% from $9.76 billion in 2001, with price increases of 3% and favorable foreign exchange of 1%, while sales volume was unchanged.

Net income was $1.97 billionb, or $1.34 diluted earnings per share, compared with $1.94 billion and $1.32 in 2001. Results include a $150 million pre-tax provision to increase litigation reserves and an $80 million gain from the sale of U.S. marketing rights for SUBOXONE and SUBUTEX. Excluding the 2002 provision and the 2001 $500 million consent decree provision, the company states that diluted earnings per share declined 10% in 2002.

The filing signals a sharp near-term earnings headwind from the U.S. switch of CLARITIN to over-the-counter status. U.S. CLARITIN prescription sales fell to $1.4 billionc from $2.7 billion, and management believes the OTC switch, a competing OTC loratadine product, and additional generic entrants will have a rapid, sharp and material adverse effect on results for an indeterminate period. Growth was driven by the INTRON franchise (PEG-INTRON and REBETOL for hepatitis C), which reached $2.7 billion, up 89%, though management expects a competing pegylated interferon product to weaken its share.

The company also faces substantial legal and regulatory exposure. It disclosed ongoing federal investigations into marketing practices, pharmacy benefit manager and managed care arrangements, and Medicaid rebate calculations, and it increased litigation reserves by $150 milliond in February 2003.

Patent litigation over the desloratadine compound patent is on appeal, and a $195 million IRS claim has not been accrued. Liquidity remains sufficient, with cash and short-term investments of $4.0 billion against $1.4 billion of short-term borrowings, though management expects that cushion to shrink in 2003.

Key Highlights

  1. Net sales rose 4% to $10.18 billion in 2002, driven by 3% price increases and 1% favorable foreign exchange, with flat sales volume.
  2. Diluted EPS was $1.34 versus $1.32 in 2001; excluding the $150 million litigation provision (2002) and $500 million consent decree provision (2001), EPS declined 10%.
  3. U.S. CLARITIN prescription sales fell to $1.4 billion from $2.7 billion after the December 2002 OTC switch, which management expects to have a rapid, sharp and material adverse effect on results.
  4. INTRON franchise sales (INTRON A, PEG-INTRON, REBETOL) rose 89% to $2.7 billion, though a competing pegylated interferon product received approval in Q4 2002.
  5. Research and development spending was $1.43 billion, or 14.0% of net sales, up from $1.31 billion in 2001.
  6. Ongoing federal investigations into marketing, rebate and off-label practices, plus a $150 million litigation reserve increase in February 2003, present significant potential liabilities.
  7. Cash and cash equivalents of $3.52 billion, with management expecting the excess of cash and short-term investments over debt to decline in 2003 as U.S. cash flow falls.

Frequently Asked Questions

  1. How much did the CLARITIN OTC switch affect the company's sales?

    U.S. CLARITIN prescription sales were $1.4 billion in 2002 versus $2.7 billion in 2001, or 14% and 28% of consolidated worldwide sales. Worldwide prescription CLARITIN sales were $1.8 billion in 2002 compared with $3.2 billion in 2001. OTC CLARITIN contributed $105 million in 2002 sales, and management expects the switch to materially reduce results for an indeterminate period.

  2. What one-time items affected 2002 and 2001 earnings?

    2002 included a $150 million pre-tax provision to increase litigation reserves and an $80 million gain from selling U.S. marketing rights for SUBOXONE and SUBUTEX. 2002 cost of sales also included a $92 million favorable adjustment from settling Biogen royalty arbitration. 2001 included a $500 million pre-tax provision for consent decree payments to the federal government.

  3. What legal and regulatory risks does the company disclose?

    The company is subject to federal grand jury and U.S. Attorney investigations into marketing practices, managed care arrangements, off-label promotion, and Medicaid rebate calculations, plus AWP pricing investigations and a Texas suit seeking about $106 million. It also faces securities class actions and an FTC administrative proceeding over K-DUR settlements. Under a consent decree, it will pay $500 million in two $250 million installments, with the second due in Q2 2003, and may face additional FDA payments through 2005.

  4. What is the company's liquidity position?

    Cash and cash equivalents were $3.52 billion and short-term investments were $481 million at year-end 2002. Short-term borrowings and current debt totaled $1.42 billion. Management expects cash flow from operations to decline in 2003 due to lower CLARITIN-related earnings and the remaining $250 million consent decree payment, and it has $1 billion of committed revolving credit facilities, with no amounts drawn at year-end.